Interesting topic to think upon this weekend. 2 biotechs using similar technology to reach a similar goal with 2 different business plans.
Sgen wants to make as many partners as it can using the high volume low return business model.
Imgn wants to bring drugs to market and keep all the proceeds without using a partner to share the profits.
One corporation will reap the short term rewards with lower risk due to the shear number of compounds in the pipeline.
The other company will take on more risks in order to seek a larger long term payoff.
It seems like Imgn hopes to become a biotech powerhouse to me but the payoff will need for their first wholly owned drug to be approved and brought to market. Kadcyla was always their giveaway as a means to an end. Kadcyla belongs to Roche and imgn has no control or even input on how it is marketed.